Skip to content

A Study of Comprehensive Intervention Strategy to Treat Attention Deficit/Hyperactivity Disorder

A Study of Comprehensive Intervention Strategy to Treat Attention Deficit/Hyperactivity Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016164
Enrollment
Unknown
Registered
2018-05-16
Start date
2018-05-30
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit/Hyperactivity Disorder

Interventions

Medication Treatment Group:Medication treatment (Atomoxetine, Ritalin, Jingling Koufuye, or Dimuningshen Koufuye)
Medication Treatment+Behavior Intervention Group:Medication treatment (Atomoxetine, Ritalin, Jingling Koufuye, or Dimuningshen Koufuye) + Behavior intervention
Medication Treatment+Behavior Intervention+Exercise Intervention Group: Medication treatment (Atomoxetine, Ritalin, Jingling Koufuye, or Dimuningshen Koufuye) + Behavior intervention + Exercise interv

Sponsors

Beijing Anding Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Meet criteria for DSM-5 Attention Deficit/Hyperactivity Disorder (ADHD); 2. Male and female patients of age 6-16 years with normal eyesight; 3. WISC-CR?70; 4. In a stable condition, capable of participating in the assessment of cognitive function; 5. Didn't receive medical treatment of stimulants, antiepileptic drugs, benzodiazepines or other psychotic medications in the last 2 weeks; 6. Capable of cooperating with investigators in assessments; 7. Consent of patient and his/her parents.

Exclusion criteria

Exclusion criteria: 1) Severe physical diseases, Angle-closure glaucoma, history of epilepsy; 2) Agoraphobia, or severe anxiety/fear for enclosed space; 3) Comorbidity with mental retardation, autism spectrum disorder or other developmental disorders; 4) Comorbidity with schizophrenia, bipolar affective disorder or other severe mental diseases; 5) Previously treated with atomoxetine but appeared ineffective, or had severe adverse events; 6) Patients considered not eligible for the trials by investigators.

Design outcomes

Secondary

MeasureTime frame
Parent Symptom Questionnaire, PSQ;(Strengths and Difficulties Questionnaire, SDQ;Behavior Rating Inventory of Executive Function, BRIEF;ADHD Knowing Questionnaire;Treatment Emergent Symptom Scale, TESS;

Primary

MeasureTime frame
Swanson, Nolan and Pelham Teacher and Parent Rating Scale,SNAP-IV;

Countries

China

Contacts

Public ContactYi Zheng

Beijing Anding Hospital Capital Medical University

dr.zheng@tom.com+86 010-58303181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026